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Abstract
Stereotactic radiosurgery (SRS) is one of the treatment modalities for benign intra-cranial tumor, especially 
for the tumor located next to the critical neural structure. The prescribed dose for radiosurgery depends on 
the maximal tumor diameter and surrounding normal tissue tolerance dose. This cross sectional study was 
conducted to evaluate the physician’s tendency in radiosurgery dose prescription. We observed treatment 
planning data of 32 patients with benign intra-cranial tumor, which had been treated with SRS at Dr. Cipto 
Mangunkusumo National Hospital in 2009-2010. The peripheral dose, organ at risk (OAR) dose limitiation 
and maximum tumor diameter were recorded. We compared our SRS dose with dose limitation, which 
allowed safer dosing based on maximal tumor diameter perspective and the nearest OAR dose constraint. 
From maximal tumor diameter perspective, we prescribed mean±SD radiosurgery doses, which were 
11.63±2.21Gy, 10.21±1.29Gy and 9.88±1.07Gy for the tumor size ≤2cm, 2.01-3cm and 3,01-4cm respectively. 
Our radiosurgery dose was the lowest than dose limitation based on the nearest OAR perspective, followed 
by maximal tumor diameter perspective. It was concluded that radiosurgery dose had the tendency to be 
influenced by surrounding healthy tissue tolerance rather than maximal tumor diameter.
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Kecenderungan Dokter dalam Menentukan Dosis Stereotactic 
Radiosurgery  untuk Tumor Jinak Intrakranial di 
RSUP Nasional dr. Cipto Mangunkusumo, Jakarta
Abstrak
Stereotactic radiosurgery (SRS) merupakan salah satu modalitas pengobatan tumor jinak intra-kranial 
terutama untuk tumor yang berdekatan dengan struktur saraf penting. Penentuan dosis pada radiosurgery 
tergantung pada diameter tumor maksimal dan dosis toleransi jaringan sehat sekitarnya. Penelitian ini 
dilakukan untuk mengevaluasi kecenderungan dokter dalam menentukan dosis radiosurgery. Penelitian cross 
sectional ini mengevaluasi data perencanaan radiasi dari 32 pasien dengan tumor jinak intra-kranial yang 
telah dilakukan prosedur SRS di RS dr.Cipto Mangunkusumo pada tahun 2009-2010. Dilakukan pencatatan 
dosis perifer tumor, dosis toleransi jaringan sehat dan diameter tumor maksimal. Dosis SRS dibandingkan 
dengan batasan dosis aman yang diperbolehkan berdasarkan aspek diameter tumor maksimal dan dosis 
toleransi jaringan sehat terdekat. Dari aspek diameter tumor maksimal, diberikan dosis radiosurgery rata-
rata±SD sebesar 11,63±2,21Gy, 10,21±1,29Gy dan 9,88±1,07Gy untuk ukuran tumor ≤2cm, 2,01-3cm dan 
3,01-4cm. Dosis radiosurgery yang kami berikan lebih rendah dibandingkan dengan dosis tolerasi jaringan 
sehat sekitarnya diikuti dengan batasan dosis berdasarkan aspek diameter tumor maksimal. Disimpulkan 
bahwa penentuan dosis radiosurgery lebih dipengaruhi oleh dosis toleransi jaringan sehat sekitarnya daripada 
diameter tumor maksimal.
Kata kunci: stereotaktik, radiosurgery, tumor jinak, dosis.
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Introduction
Stereotactic is derived from the Greek word 
“stereos” which means solid and “taxis” which means 
arrangement or order. Stereotactic radiosurgery 
(SRS) implies the delivery of a single large dose 
of focused radiation, which can kill tumor cell and 
/or obliterate blood vessels with the application 
of a three-dimensional coordinate system to 
navigate the localization of small targets inside 
the skull cavity. The use of high-dose radiation in 
radiosurgery requires three-dimensional mapping 
technique to guide radiosurgery procedure because 
it will produce precise target localization while 
minimizing radiation dose to surrounding normal 
tissue.  The efficacy of stereotactic radiosurgery 
allows high probability of local control comparable 
to surgery.1-3
The definitive treatment of benign intra-cranial 
tumors is surgery. In many cases, a benign tumor 
is located in areas where there are many vital 
structures surrounding it. Therefore, the surgery 
is difficult to do because surgery can cause high 
morbidity and mortality. Because of the large risk of 
complications, radiotherapy becomes an alternative 
treatment. In a benign tumor, radiotherapy is less 
responsive because it is classified as a radio-
resistant tumor. The objective of radiosurgery in 
benign tumor is no progression in tumor size. Tumor 
treated with radiosurgery needs latent period to 
shrink.2,4,5
In parallel with the development of radiobiology, 
knowledge of the benign tumor’s radio-sensitivity 
to fractionation begins to be known. From 
several studies, a benign tumor has a α/β ratio 
approximately 3Gray (Gy). With a low α/β ratio, 
re-oxygenation plays a less important role, which 
causes fractionation less important. So in small 
low α/β ratio tumor, it is more reasonable to give 
a single fraction or hypofractionation. Radiosurgery 
process does not require much time. The whole 
process usually requires 4-5 hours.2,6,7 
This study was conducted to evaluate factor that 
influences the physician’s tendency in radiosurgery 
dose determination in radiosurgery procedure at 
Dr. Cipto Mangunkusumo Hospital, Jakarta. 
Methods
This cross sectional study analyzed 32 
treatment planning data from the medical record 
for radiosurgery of benign tumor, which had been 
undergone radiosurgery procedure in Department 
of Radiotherapy Dr. Cipto Mangunkusumo 
National Hospital, Jakarta, from January 2009 
until December 2010. SRS was delivered using 
Elekta® Synergy S linear accelerator (LINAC) and 
radiosurgery dose calculation was performed in 
Precise PLAN® treatment planning system.
The data collected were gender, age, maximal 
tumor diameter, tumor volume, and tumor dose. We 
collected information of the dose from treatment 
planning data in the medical record in the form 
of dose volume histogram (DVH). Tumor dose is 
determined by dose at the edge (peripheral) of 
tumor. The organ at risk (OAR) dose is determined 
by the maximum dose (Dmax) stated in the DVH. 
For benign tumor, we classified into group of the 
tumor. The group consisted of pituitary adenoma, 
skull base meningioma, convexity meningioma, 
craniopharyngioma, acoustic neuroma and pineal 
tumor.
From these tumor groups, we evaluated factor 
that influences the radiosurgery dose determination 
based on maximal tumor diameter and OAR 
tolerance dose. OAR dose was determined based 
on the lowest OAR tolerance dose based on the 
critical structure located next to the tumor. 
All statistical analysis was performed using 
the Statistical Package for Social Sciences (SPSS 
version 17.0, Chicago, USA). 
Results
Characteristic data are shown in Table 1. Most 
of the patients were female and acoustic neuroma 
was the most found benign tumor in this study.
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Table 1.  Characteristics of Benign Intra-
cranial Tumors Patients, Underwent 
Radiosurgery at Dr. Cipto 
Mangunkusumo National Hospital, 
2009-2010
Characteristic n (%)
Gender
     Male
     Female
Diagnostic
     Acoustic neuroma
     Pituitary adenoma
     Skull base meningioma
     Convexity meningioma
     Pineal tumor
     Craniopharyngioma
Maximal tumor diameter group
     ≤2cm
     2.01–3cm
     3.01–4cm
     >4cm
Age (years old)
     Median
     Range
Maximal tumor diameter (cm)
     Median
     Range
Tumor volume (cc)
     Median
     Range
Dose (Gy)
     Mean
     Standard deviation
7 (21.9%)
25 (78.1%)
12 (37.5%)
8 (25%)
5 (15.6%)
3 (9.4%)
3 (9.4%)
1 (3.1%)
4 (12.5%)
14 (43.7%)
12 (37.5%)
2 (6.2%)
41
7–63
2.8
0.7–5.2
6.0
0.1–35.2
10.2
1.3
Table 2. Comparison of Dose (Gy), from 
Maximal Tumor Diameter Perspective 
Compared to Dose Constraint Allowed 
by RTOG 90-05 Protocol
Maximal Tumor 
Diameter Mean Dose (SD) RTOG 90-05
≤2cm 11.63 (±2.21)Gy 24Gy
2.01–3cm 10.21 (±1.29)Gy 18Gy
3.01–4cm 9.88 (±1.07)Gy 15Gy
>3cm 10Gy N/A
Radiosurgery dose which had been performed 
at Dr. Cipto Mangunkusumo National Hospital was 
compared with the nearest OAR tolerance dose 
and the dose allowed per RTOG 90-05 protocol. We 
applied the lowest dose in RTOG 90-05, which was 
15Gy for maximum tumor diameter 31-40mm.  The 
comparison of radiosurgery dose and OAR dose 
limitation showed that the physician’s tendency 
of dose determination in radiosurgery depended 
more on OAR tolerance dose compared to maximal 
tumor diameter (Table 3 and Figure 1). One of the 
example case was acoustic neuroma which had 
been treated with radiosurgery. Figure 2 shows that 
peripheral dose was far from the brainstem.
Table 3. Radiosurgery Doses for Benign Intra-cranial Tumor and The Lowest OAR Dose 
Constraint Based on The Critical Normal Structure Located Next to Tumor
Variables Acoustic 
Neuroma
Pituitary 
Adenoma
Skull base 
Meningioma
Convexity 
Meningioma
Pineal 
Tumor
Cranio-
pharyngioma
n 12 8 5 3 3 1
Median dose 
(range) Gy
11(9-14) 9.7(9.5-10) 9.5(9-9.5) 10(9.5-13) 9.5(9.5-10) 9.5
The nearest 
OAR
Brainstem Optic 
chiasm
Optic chiasm Brain 
parenchyma
Brainstem Optic chiasm
Dose 
constraint
12.5Gy 10Gy 10Gy 12Gy 12Gy 10Gy
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Figure 1. The Comparison of Radiosurgery 
Dose at Dr. Cipto Mangunkusumo 
National Hospital with The Lowest 
OAR DoseConstraint Based on The 
Critical Structures Located Next to 
The Tumor and The Dose Allowed 
by RTOG 90-05 Based on Maximum 
Tumor Diameter.
Figure 2. Acoustic Neuroma, Treated with 
Radiosurgery. The Peripheral Dose 
was Far from Brainstem.
Discussion
 SRS is a technique that provides high-
dose radiation with a high degree of accuracy and 
coverage that conforms the shape of the target 
to obtain the desired radiobiology response and 
minimize radiation to the surrounding normal tissue. 
Based on Quantitative Analysis of Normal 
Tissue Effects in the Clinic (QUANTEC) study, 
 4 
RTOG 90-05 protocol. We applied the lowest dose in RTOG 90-05, which was 15Gy for 
maximum tumor diameter 31-40mm.  The comparison of radiosurgery dose and OAR dose 
limitation showed that the physician’s tendency of dose determination in radiosurgery 
dependedmoreon OAR tolerance dose compared to maximal tumor diameter (Table3 and 
Figure 1). One of the example case was acoustic neuroma which had been treated with 
radiosurgery.Figure 2 showsthat peripheral dose was far from the brainstem.
Table 3. Radiosurgery Doses for Benign Intra-cranial Tumor andThe Lowest OAR Dose 
Constraint Based on The Critical Normal Structure Located Next to Tumor
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Pituitary 
Adenoma
Skull base 
Meningioma
Convexity 
Meningioma
Pineal 
Tumor
Cranio-
pharyngioma
n 12 8 5 3 3 1
Median dose 
(range) Gy
11(9-14) 9.7(9.5-10) 9.5(9-9.5) 10(9.5-13) 9.5(9.5-10) 9.5
The nearest 
OAR
Brainstem Optic chiasm Optic chiasm Brain 
parenchyma
Brainstem Optic chiasm
Dose 
constraint
12.5Gy 10Gy 10Gy 12Gy 12Gy 10Gy
Figure 1. The Comparison of Radiosurgery DoseatDr. CiptoMangunkusumo National 
HospitalwithThe Lowest OAR DoseConstraint Based on The Critical Structures
Located Next to The Tumor and The Dose Allowed by RTOG 90-05 Based on 
Maximum Tumor Diameter.
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normal tissue tolerance dose is volume-dependent. 
With this immobilization technique and image-
guided radiosurgery delivery during verification in 
SRS will minimize the set-up margin. It will reduce 
treatment volume and make the risk of complications 
become lower. The target accuracy is high because 
the utilization of three-dimensional mapping system. 
Because of immobilization, three-dimensional 
mapping system and image-guided, we can deliver 
a high radiation dose which can produce desired 
radiobiology responses (tumor ablation and vascular 
obliteration). The effect of radiosurgery in tumor 
immunity is still being studied. While in radiotherapy, 
we try to deliver homogenous dose distribution, 
in radiosurgery we deliver heterogeneous dose 
distribution with steep dose gradient. It is expected 
with heterogeneous dose distribution we try to create 
hot spot in tumor, which will ablate the radio resistant 
clonogenic tumor cell.2,3,7
The prescribed dose for radiosurgery depends 
on the maximal tumor diameter and tolerance dose 
to surrounding normal tissue. Based on RTOG 
90-05, we can deliver radiosurgery safe with the 
maximum prescribed dose is 24Gy, 18Gy and 15Gy 
to the tumor size of ≤20mm, 21-30mm and 31-
40mm in maximum diameter, with a low probability 
of brain necrosis. Meanwhile, for the guidance for 
dose limitation of surrounding critical healthy tissue 
was based on QUANTEC study. The important 
critical tissues are brainstem, optic chiasm and 
optic nerve. The dose limitation for such organ 
are Dmax optic chiasm and optic nerve <10-12Gy, 
Dmax brain stem <12-12.5Gy.6,8-11
Some benign intra-cranial tumors can be treated 
with radiosurgery, including pituitary adenoma, 
acoustic neuroma, meningioma, craniopharyngioma 
and pineocytoma. They usually do not respond 
well to fractionated radiotherapy because of the 
radio-resistant nature. The α/β ratio is assumed 
low, usually approximately 3Gy. In the point of view 
of efficacy, there is no advantaged which can be 
gained from fractionated radiotherapy compared 
to single fraction radiosurgery in the small benign 
tumor, meanwhile single fraction is more convenient 
for the patient compared to multiple fractions.12,13
From our experience, we must consider the 
maximum tumor diameter and OAR dose limitation 
for determination of prescribed dose. We will 
determine the dose based on the lowest dose, 
which will cause the lowest toxicity. In this study, we 
observed that surrounding healthy tissue tolerance 
dose had the lower dose than dose limitation from 
maximal tumor diameter perspective. 
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We delivered radiosurgery dose below many 
other studies because in many of our case, the tumor 
was located next to critical normal tissue. As an 
example, skull base meningioma was attached to the 
brainstem. The radiosurgery dose for meningioma 
is usually 14-16Gy, but if the meningioma located 
attached to the optic chiasm, we can only prescribe 
the dose not more than optic chiasm tolerance 
dose, which is 10Gy based on QUANTEC study. In 
our experience, we only delivered 9.5Gy to tumor 
peripheral. So if we compare the dose between skull 
base meningioma and convexity meningioma, we 
can deliver the higher dose in convexity meningioma 
compared with skull base meningioma. If we review 
the result of RTOG 90-05, we can only deliver that 
dose in non-eloquent area of the brain, in which the 
tumor location is far from critical OAR.14-22
Conclusions
The dose determination in radiosurgery 
depended on the maximal tumor diameter and 
OAR tolerance dose, but the physician’s tendency 
in dose prescription was more in OAR tolerance 
dose compared with maximal tumor diameter 
perspective.
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